

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 October 2024 (31.10.2024)



(10) International Publication Number
WO 2024/225441 A1

(51) International Patent Classification:

A61K 31/496 (2006.01) A61P 25/18 (2006.01)
A61K 9/00 (2006.01)

(21) International Application Number:

PCT/JP2024/016465

(22) International Filing Date:

26 April 2024 (26.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/498,313	26 April 2023 (26.04.2023)	US
63/506,624	07 June 2023 (07.06.2023)	US
63/637,079	22 April 2024 (22.04.2024)	US

(71) Applicant: OTSUKA PHARMACEUTICAL CO., LTD.

[JP/JP]; 2-9, Kanda Tsukasa-machi, Chiyoda-ku, Tokyo,
1018535 (JP).

(72) Inventors: HARLIN, Matthew; c/o OTSUKA AMERICA

PHARMACEUTICAL, INC., 2440 Research Boulevard,
Rockville, Maryland, 20850 (US). WANG, Xiaofeng; c/o
OTSUKA AMERICA PHARMACEUTICAL, INC., 2440
Research Boulevard, Rockville, Maryland, 20850 (US).
WANG, Yanlin; c/o OTSUKA AMERICA PHARMA-
CEUTICAL, INC., 2440 Research Boulevard, Rockville,
Maryland, 20850 (US). RAOUFINIA, Arash; c/o OTSU-
KA AMERICA PHARMACEUTICAL, INC., 2440 Re-
search Boulevard, Rockville, Maryland, 20850 (US).

(74) Agent: YAMAO, Norihito et al.; AOYAMA & PART-

NERS, Osaka Umeda Twin Towers North, 8-1, Kaku-
da-cho, Kita-ku, Osaka-shi, Osaka, 5300017 (JP).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: DOSE INITIATION FOR SCHIZOPHRENIA OR BIPOLAR I DISORDER TREATMENT WITH ARIPIPRAZOLE

(57) Abstract: The present disclosure is directed to methods of dose initiation for an aripiprazole treatment to a patient in need thereof by administering two, separate injections of aripiprazole with a first aripiprazole injection of a long acting injectable (LAI) and a second aripiprazole injection of a once-monthly injectable (AOM) on a first day of the aripiprazole treatment, and a single dose of oral aripiprazole. Maintenance dosing occurs about two months after the first day of the aripiprazole treatment using a maintenance dose of the LAI. The present methods are applicable to both the deltoid and gluteal administration sites.



WO 2024/225441 A1